ArticleJournal of bone and mineral metabolism2015
Chronic kidney disease and bone metabolism.
Article in Journal of bone and mineral metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- The Efficacy of Low-intensity Vibration to Improve Bone Health in Patients with End-stage Renal Disease Is Highly Dependent on Compliance and Muscle Response.Academic radiology · 2017Trial
- Multi-system Mechanisms in the Anti-osteoporotic Effects of Herbal Natural Products.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Integrating deep learning and machine learning for improved CKD-related cortical bone assessment in HRpQCT images: A pilot study.Bone reports · 2025Article
- Article
- Association of RAGE gene polymorphisms (rs2070600 and rs2071288) with bone metabolism disturbances in patients with chronic kidney disease.International journal of molecular and cellular medicine · 2025Article
- Inhibition of Indoxyl Sulfate-Induced Reactive Oxygen Species-Related Ferroptosis Alleviates Renal Cell Injury In Vitro and Chronic Kidney Disease Progression In Vivo.Antioxidants (Basel, Switzerland) · 2023Article
- Evaluation of myostatin as a possible regulator and marker of skeletal muscle-cortical bone interaction in adults.Journal of bone and mineral metabolism · 2021Article
- Resveratrol Rescue Indoxyl Sulfate-Induced Deterioration of Osteoblastogenesis via the Aryl Hydrocarbon Receptor /MAPK Pathway.International journal of molecular sciences · 2020Article
- High Levels of Physical Activity May Promote a Reduction in Bone Mineral Density in Peritoneal Dialysis.Medicina (Kaunas, Lithuania) · 2020Article
- Concentration and Duration of Indoxyl Sulfate Exposure Affects Osteoclastogenesis by Regulating NFATc1 via Aryl Hydrocarbon Receptor.International journal of molecular sciences · 2020Article
- Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study.BMC nephrology · 2019Article
- Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.Clinical kidney journal · 2019Article
- Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.Toxins · 2018Review
- Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: A report of 9 cases.Experimental and therapeutic medicine · 2018Article
- Cortical bone analysis in a predialysis population: a comparison with a dialysis population.Journal of bone and mineral metabolism · 2017Article
- Article
- Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.International urology and nephrology · 2017Article
- Safety and efficacy of denosumab in osteoporotic hemodialysed patients.Journal of nephrology · 2017Observational
- Chronic kidney disease and fragility fracture.Clinical and experimental nephrology · 2017Review
- The Association between Urine Albumin to Creatinine Ratio and Osteoporosis in Postmenopausal Women with Type 2 Diabetes.Journal of bone metabolism · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease-related mineral and bone disease (CKD-MBD) is a syndrome defined as a systemic mineral metabolic disorder associated with CKD, and the term renal osteodystrophy indicates a pathomorphological concept of bone lesions associated with CKD-MBD. Cortical bone thinning, abnormalities in bone turnover and primary/secondary mineralization, elevated levels of circulating sclerostin, increased apoptosis in osteoblasts and osteocytes, disturbance of the coupling phenomenon, iatrogenic factors, accumulated micro-crackles, crystal/collagen disorientation, and chemical modification of collagen crosslinks are all possible candidates found in CKD that could promote osteopenia and/or bone fragility. Some of above factors are the consequences of abnormal systemic mineral metabolism but for others it seem unlikely. We have used the term uremic osteoporosis to describe the uremia-induced bone fragility which is not derived from abnormal systemic mineral metabolism. Interestingly, the disease aspect of uremic osteoporosis appears to be similar to that of senile osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.